University of California San Francisco

Atreya.jpg
Chloe Atreya, MD, PhD

Assistant Clinical Professor
Department of Medicine 

Address

550 16th Street, #6556
San Francisco, CA 94158
United States

Phone: 415-353-9888
Fax: 415-353-7779

ORCID: 0000-0003-2954-1727

Biography

Dr. Chloe E. Atreya specializes in gastrointestinal cancer, particularly colorectal cancer, at the UCSF Helen Diller Comprehensive Cancer Center. She also co-directs the Integrative Onolcogy Program and Research Hub. Her research focuses on the interplay of tumor genetics and response to therapies for colorectal cancer, with the goal of improving patient outcomes and quality of life by personalizing treatment.

Awards & Honors

Award Conferred By Date
Clinical Innovation Center Inside Out Accelerator Award 2017
The Marcus Program in Precision Medicine Innovation Seeding Bold Ideas Award 2017
The Ernest H. Rosenbaum MD Commitment to Patient Care Award, UCSF Symptom Management Service 2014
Alliance for Clinical Trials in Oncology Foundation Investigator Award 2012
American Cancer Society Postdoctoral Fellowship 11-183-01-TBG 2011
Conquer Cancer Foundation of the American Society of Clinical Oncology Young Investigator Award 2011

Education

Institution Degree Dept or School End Date
University of California Diversity, Equity, and Inclusion Champion Training 2019
University of California Diversity, Equity, and Inclusion Champion Training 11/2019
Yale University MD, PhD School of Medicine 2005
Princeton University BA 1998

Clinical Trials

  1. Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases (NCT03844750)
    Related Conditions: Malignant Neoplasm, Colorectal Cancer, Immunotherapy, Colorectal Tumor, Neoplasms| Start Date: | End Date:
  2. Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery (NCT03396926)
    Related Conditions: Microsatellite Stable, Mismatch Repair Protein Proficient, Colorectal Cancer, Colorectal Tumor| Start Date: | End Date:
  3. Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer (NCT04044430)
    Related Conditions: Colon Cancer, Colorectal Cancer, Rectal Cancer, Colorectal Tumor| Start Date: | End Date:
  4. Web-based Mindfulness Meditation in Reducing Distress in Participants With Metastatic Gastrointestinal Cancer and Their Caregivers (NCT03528863)
    Related Conditions: Caregivers, Gastrointestinal Carcinoma, Meditation, Mindfulness, Gastrointestinal Cancer| Start Date: | End Date:
  5. Mindfulness Meditation Intervention for Colorectal Cancer Patients and Caregivers (NCT02423720)
    Related Conditions: Colorectal Cancer, Caregivers, Meditation, Mindfulness, Colorectal Tumor| Start Date: | End Date:

Grants and Funding

  • Understanding Intrinsic Resistance to Direct KRAS Inhibition In colorectal Cancers | NIH-NCI | 2022-01-01 - 2026-12-21 | Role: Co-Investigator
  • Optimization of a remote intervention to improve nutrition and physical activity in colorectal cancer survivors | NIH/NCI | 2020-09-01 - 2025-08-01 | Role: Co-Investigator
  • Kinome-guided Targeting of Cooperative Dependencies in BRAF and KRAS Mutated Colorectal Cancer | NIH | 2019-06-01 - 2024-05-31 | Role: Principal Investigator
  • (PQ10) Harnessing the human gut microbiome to predict chemotherapy outcomes | NIH | 2018-06-21 - 2021-05-31 | Role: Co-Principal Investigator
  • Targeting of Aberrant Signaling in Patient-Derived Colorectal Cancer Models | NIH | 2013-09-15 - 2019-04-30 | Role: Principal Investigator

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 65
  1. Expansion of a bacterial operon during cancer treatment ameliorates drug toxicity.
    Trepka KR, Kidder WA, Kyaw TS, Halsey T, Olson CA, Ortega EF, Noecker C, Upadhyay V, Stanfield D, Steiding P, Guthrie BGH, Spanogiannopoulos P, Dumlao D, Turnbaugh JA, Stachler MD, Van Blarigan EL, Venook AP, Atreya CE, Turnbaugh PJ| | PubMed
  2. Metagenomic analysis during capecitabine therapy reveals microbial chemoprotective mechanisms and predicts drug toxicity in colorectal cancer patients.
    Hillege LE, Trepka KR, Ziemons J, Aarnoutse R, Guthrie BGH, de Vos-Geelen J, Valkenburg-van Iersel L, van Hellemond IEG, Baars A, Vestjens JHMJ, Penders J, Deutschbauer A, Atreya CE, Kidder WA, Turnbaugh PJ, Smidt ML| | PubMed
  3. Synchronous or metachronous breast and colorectal cancers in younger-than-average-age patients: a case series.
    Silverstein J, Wright F, Stanfield D, Chien AJ, Wong JM, Park JW, Blanco A, Van Loon K, Atreya CE| | PubMed
  4. Association between gastrointestinal symptoms and specialty care utilization among colon cancer survivors: a cohort study.
    Edwards AL, Trang K, Tolstykh IV, Van Blarigan EL, Van Loon K, Laffan A, Stanfield D, Steiding P, Neuhaus J, Atreya CE, Piawah S, Venook AP, Varma MG| | PubMed
  5. Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment.
    Parikh AR, Chee BH, Tsai J, Rich TA, Price KS, Patel SA, Zhang L, Ibrahim F, Esquivel M, Van Seventer EE, Jarnagin JX, Raymond VM, Corvera CU, Hirose K, Nakakura EK, Corcoran RB, Van Loon K, Atreya CE| | PubMed
  6. Mindfulness-Based Group Medical Visits: Strategies to Improve Equitable Access and Inclusion for Diverse Patients in Cancer Treatment.
    Mishra KK, Leung IC, Chao MT, Thompson-Lastad A, Pollak C, Dhruva A, Hartogensis W, Lister M, Cheng SW, Atreya CE| | PubMed
  7. Associations between the Gut Microbiota, Race, and Ethnicity of Patients with Colorectal Cancer: A Pilot and Feasibility Study.
    Piawah S, Kyaw TS, Trepka K, Stewart AL, Mora RV, Stanfield D, Levine K, Van Blarigan EL, Venook A, Turnbaugh PJ, Nguyen T, Atreya CE| | PubMed
  8. Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults With Cancer: Society for Integrative Oncology-ASCO Guideline.
    Carlson LE, Ismaila N, Addington EL, Asher GN, Atreya C, Balneaves LG, Bradt J, Fuller-Shavel N, Goodman J, Hoffman CJ, Huston A, Mehta A, Paller CJ, Richardson K, Seely D, Siwik CJ, Temel JS, Rowland JH| | PubMed
  9. Variety of Fruit and Vegetables and Alcohol Intake are Associated with Gut Microbial Species and Gene Abundance in Colorectal Cancer Survivors.
    Kyaw TS, Upadhyay V, Tolstykh I, Van Loon K, Laffan A, Stanfield D, Gempis D, Kenfield SA, Chan JM, Piawah S, Atreya CE, Ng K, Venook A, Kidder W, Turnbaugh PJ, Van Blarigan EL| | PubMed
  10. Sexual function remains persistently low in women after treatment for colorectal cancer and anal squamous cell carcinoma.
    Savoie MB, Paciorek A, Van Loon K, Anwar M, Atreya CE, Johnson PC, Kenfield SA, Laffan A, Levin AO, Smith JF, Stanfield D, Venook A, Zhang L, Van Blarigan EL, Rowen T| | PubMed
  11. Quality of life among colorectal cancer survivors participating in a pilot randomized controlled trial of a web-based dietary intervention with text messages.
    Wang L, Langlais C, Kenfield SA, Van Loon K, Laffan A, Atreya CE, Chan JM, Zhang L, Allen IE, Miaskowski C, Fukuoka Y, Meyerhardt JA, Venook AP, Van Blarigan EL| | PubMed
  12. A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors.
    Ruiz-Saenz A, Atreya CE, Wang C, Pan B, Dreyer CA, Brunen D, Prahallad A, Muñoz DP, Ramms DJ, Burghi V, Spassov DS, Fewings E, Hwang YC, Cowdrey C, Moelders C, Schwarzer C, Wolf DM, Hann B, VandenBerg SR, Shokat K, Moasser MM, Bernards R, Gutkind JS, van 't Veer LJ, Coppé JP| | PubMed
  13. Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases.
    Fidelman N, Atreya CE, Griffith M, Milloy MA, Carnevale J, Cinar P, Venook AP, Van Loon K| | PubMed
  14. Optimizing intervention tools to improve nutrition and physical activity for colorectal cancer survivors (Tools To Be Fit): Study protocol of a randomized factorial experiment.
    Kenfield SA, Philip EJ, Phillips SM, Meyerhardt JA, Chan JM, Atreya CE, Kim MO, Harris Q, Steiding P, Macaire G, McCullough ML, Piawah S, Johnson WY, Kurttila FA, Lewis WL, Pesmen C, Watson Y, Van Blarigan EL| | PubMed
  15. Association between adherence to the American Cancer Society Nutrition and Physical Activity Guidelines and stool frequency among colon cancer survivors: a cohort study.
    Greenberg AL, Tolstykh IV, Van Loon K, Laffan A, Stanfield D, Steiding P, Kenfield SA, Chan JM, Atreya CE, Piawah S, Kidder W, Venook AP, Van Blarigan EL, Varma MG| | PubMed
  16. Host and gut bacteria share metabolic pathways for anti-cancer drug metabolism.
    Spanogiannopoulos P, Kyaw TS, Guthrie BGH, Bradley PH, Lee JV, Melamed J, Malig YNA, Lam KN, Gempis D, Sandy M, Kidder W, Van Blarigan EL, Atreya CE, Venook A, Gerona RR, Goga A, Pollard KS, Turnbaugh PJ| | PubMed
  17. mHealth Interventions to Promote a Healthy Diet and Physical Activity among Cancer Survivors: A Systematic Review of Randomized Controlled Trials.
    Wang L, Langlais CS, Kenfield SA, Chan JM, Graff RE, Allen IE, Atreya CE, Van Blarigan EL| | PubMed
  18. The Gut Microbiome in Colorectal Cancer.
    Piawah S, Walker EJ, Van Blarigan EL, Atreya CE| | PubMed
  19. Quality of life of colorectal cancer survivors participating in a pilot randomized controlled trial of physical activity trackers and daily text messages.
    Chan H, Van Loon K, Kenfield SA, Chan JM, Mitchell E, Zhang L, Paciorek A, Joseph G, Laffan A, Atreya C, Fukuoka Y, Miaskowski C, Meyerhardt JA, Venook AP, Van Blarigan EL| | PubMed
  20. Feasibility and Acceptability of a Physical Activity Tracker and Text Messages to Promote Physical Activity During Chemotherapy for Colorectal Cancer: Pilot Randomized Controlled Trial (Smart Pace II).
    Van Blarigan EL, Dhruva A, Atreya CE, Kenfield SA, Chan JM, Milloy A, Kim I, Steiding P, Laffan A, Zhang L, Piawah S, Fukuoka Y, Miaskowski C, Hecht FM, Kim MO, Venook AP, Van Loon K| | PubMed
  21. Characteristics and Growth Rate of Lung Metastases in Patients With Primary Gastrointestinal Malignancies and Lung-dominant Metastatic Disease: A Retrospective Cohort Analysis.
    Burns S, Vella M, Paciorek A, Zhang L, Atreya CE, Feng M, Kelley RK, Tempero MA, Van Loon K, Ko AH| | PubMed
  22. Discovering dominant tumor immune archetypes in a pan-cancer census.
    Combes AJ, Samad B, Tsui J, Chew NW, Yan P, Reeder GC, Kushnoor D, Shen A, Davidson B, Barczak AJ, Adkisson M, Edwards A, Naser M, Barry KC, Courau T, Hammoudi T, Argüello RJ, Rao AA, Olshen AB, Immunoprofiler Consortium, Cai C, Zhan J, Davis KC, Kelley RK, Chapman JS, Atreya CE, Patel A, Daud AI, Ha P, Diaz AA, Kratz JR, Collisson EA, Fragiadakis GK, Erle DJ, Boissonnas A, Asthana S, Chan V, Krummel MF| | PubMed
  23. Being Present 2.0: Online Mindfulness-Based Program for Metastatic Gastrointestinal Cancer Patients and Caregivers.
    Dragomanovich HM, Dhruva A, Ekman E, Schoenbeck KL, Kubo A, Van Blarigan EL, Borno HT, Esquivel M, Chee B, Campanella M, Philip EJ, Rettger JP, Rosenthal B, Van Loon K, Venook AP, Boscardin C, Moran P, Hecht FM, Atreya CE| | PubMed
  24. Molecular and Radiological Features of Microsatellite Stable Colorectal Cancer Cases With Dramatic Responses to Immunotherapy.
    Keenan BP, VAN Loon K, Khilnani AD, Fidelman N, Behr SC, Atreya CE, Oh DY| | PubMed
  25. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).
    Kopetz S, Guthrie KA, Morris VK, Lenz HJ, Magliocco AM, Maru D, Yan Y, Lanman R, Manyam G, Hong DS, Sorokin A, Atreya CE, Diaz LA, Allegra C, Raghav KP, Wang SE, Lieu CH, McDonough SL, Philip PA, Hochster HS| | PubMed
  26. Molecular Insights in Transmission of Cancer From an Organ Donor to Four Transplant Recipients.
    Atreya CE, Collisson EA, Park M, Grenert JP, Behr SC, Gonzalez A, Chou J, Maisel S, Friedlander TW, Freise CE, Shoji J, Semrad TJ, Van Ziffle J, Chin-Hong P| | PubMed
  27. Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial.
    Van Blarigan EL, Zhang S, Ou FS, Venlo A, Ng K, Atreya C, Van Loon K, Niedzwiecki D, Giovannucci E, Wolfe EG, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA| | PubMed
  28. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.
    Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S| | PubMed
  29. Factors Impacting Differential Outcomes in the Definitive Radiation Treatment of Anal Cancer Between HIV-Positive and HIV-Negative Patients.
    Susko M, Wang CJ, Lazar AA, Kim S, Laffan A, Feng M, Ko A, Venook AP, Atreya CE, Van Loon K, Anwar M| | PubMed
  30. Probing the tumor micro(b)environment.
    Atreya CE, Turnbaugh PJ| | PubMed
  31. Embedded palliative care for patients with metastatic colorectal cancer: a mixed-methods pilot study.
    Bischoff KE, Zapata C, Sedki S, Ursem C, O'Riordan DL, England AE, Thompson N, Alfaro A, Rabow MW, Atreya CE| | PubMed
  32. BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer.
    Middleton G, Yang Y, Campbell CD, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, De Vos F, Van Cutsem E, Millholland JM, Brase JC, Rangwala F, Gasal E, Corcoran RB| | PubMed
  33. Clinicopathologic Characteristics and Impact of Oophorectomy for Ovarian Metastases from Colorectal Cancer.
    Ursem C, Zhou M, Paciorek A, Atreya CE, Ko AH, Venook A, Zhang L, Van Loon K| | PubMed
  34. Postoperative Exacerbation of Oxaliplatin-induced Neurotoxicity in Gastrointestinal Cancers: A Case Series.
    Gonzalez A, Walker EJ, Van Loon K, Cinar P, Atreya CE| | PubMed
  35. Feasibility and Acceptability of a Web-Based Dietary Intervention with Text Messages for Colorectal Cancer: A Randomized Pilot Trial.
    Van Blarigan EL, Kenfield SA, Chan JM, Van Loon K, Paciorek A, Zhang L, Chan H, Savoie MB, Bocobo AG, Liu VN, Wong LX, Laffan A, Atreya CE, Miaskowski C, Fukuoka Y, Meyerhardt JA, Venook AP| | PubMed
  36. Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation.
    Savoie MB, Paciorek A, Zhang L, Van Blarigan EL, Sommovilla N, Abrams D, Atreya CE, Bergsland EK, Chern H, Kelley RK, Ko A, Laffan A, Sarin A, Varma MG, Venook AP, Van Loon K| | PubMed
  37. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.
    Le DT, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, Burge M, O'Neil B, Kavan P, Yoshino T, Guimbaud R, Taniguchi H, Elez E, Al-Batran SE, Boland PM, Crocenzi T, Atreya CE, Cui Y, Dai T, Marinello P, Diaz LA, André T| | PubMed
  38. A multi-modal data resource for investigating topographic heterogeneity in patient-derived xenograft tumors.
    Rajaram S, Roth MA, Malato J, VandenBerg S, Hann B, Atreya CE, Altschuler SJ, Wu LF| | PubMed
  39. Hormone receptor expression of colorectal cancer diagnosed during the peri-partum period.
    Silverstein J, Kidder W, Fisher S, Hope TA, Maisel S, Ng D, Van Ziffle J, Atreya CE, Van Loon K| | PubMed
  40. Improving Access to Integrative Oncology Through Group Medical Visits: A Pilot Implementation Project.
    Thompson-Lastad A, Atreya CE, Chao MT, Pollak C, Dhruva A, Santana T, Abrams DI| | PubMed
  41. Self-monitoring and reminder text messages to increase physical activity in colorectal cancer survivors (Smart Pace): a pilot randomized controlled trial.
    Van Blarigan EL, Chan H, Van Loon K, Kenfield SA, Chan JM, Mitchell E, Zhang L, Paciorek A, Joseph G, Laffan A, Atreya CE, Fukuoka Y, Miaskowski C, Meyerhardt JA, Venook AP| | PubMed
  42. Of Microbes and Microsatellites.
    Atreya CE, Venook AP| | PubMed
  43. Applying New Models of Care to Meet Patient Needs in Integrative Oncology.
    Dhruva A, Atreya CE, Chao MT| | PubMed
  44. Being Present: A single-arm feasibility study of audio-based mindfulness meditation for colorectal cancer patients and caregivers.
    Atreya CE, Kubo A, Borno HT, Rosenthal B, Campanella M, Rettger JP, Joseph G, Allen IE, Venook AP, Altschuler A, Dhruva A| | PubMed
  45. Emerging treatment options for BRAF-mutant colorectal cancer.
    Ursem C, Atreya CE, Van Loon K| | PubMed
  46. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.
    Corcoran RB, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, Humblet Y, De Vos F, Jung AS, Brase JC, Jaeger S, Bettinger S, Mookerjee B, Rangwala F, Van Cutsem E| | PubMed
  47. Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer.
    Strickler JH, Loree JM, Ahronian LG, Parikh AR, Niedzwiecki D, Pereira AAL, McKinney M, Korn WM, Atreya CE, Banks KC, Nagy RJ, Meric-Bernstam F, Lanman RB, Talasaz A, Tsigelny IF, Corcoran RB, Kopetz S| | PubMed
  48. Sampling strategies to capture single-cell heterogeneity.
    Rajaram S, Heinrich LE, Gordan JD, Avva J, Bonness KM, Witkiewicz AK, Malter JS, Atreya CE, Warren RS, Wu LF, Altschuler SJ| | PubMed
  49. Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.
    Parikh A, Atreya C, Korn WM, Venook AP| | PubMed
  50. Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches.
    Atreya CE, Yaeger R, Chu E| | PubMed
  51. Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location.
    Atreya CE, Greene C, McWhirter RM, Ikram NS, Allen IE, Van Loon K, Venook AP, Yeh BM, Behr SC| | PubMed
  52. Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study.
    Fidelman N, Kerlan RK, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland EK, Kelley RK, Ko AH, Korn WM, Van Loon K, McWhirter RM, Luan J, Johanson C, Venook AP| | PubMed
  53. Role of Biologics in Colon Cancer: Still Not Clear.
    Atreya CE, Venook AP| | PubMed
  54. A phase II study of axitinib in advanced neuroendocrine tumors.
    Strosberg JR, Cives M, Hwang J, Weber T, Nickerson M, Atreya CE, Venook A, Kelley RK, Valone T, Morse B, Coppola D, Bergsland EK| | PubMed
  55. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
    Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S| | PubMed
  56. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas.
    Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA| | PubMed
  57. Expanded RAS: refining the patient population.
    Atreya CE, Corcoran RB, Kopetz S| | PubMed
  58. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.
    Song EK, Tai WM, Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Pitts TM, Wang G, Blatchford P, Yahn R, Kaplan J, Tan AC, Atreya CE, Eckhardt G, Kelley RK, Venook A, Kwak EL, Ryan D, Arcaroli JJ| | PubMed
  59. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803.
    Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Ye C, Saltz LB, Bertagnolli MM| | PubMed
  60. Cancer Medicine
    Atreya CE, Sangale Z, Xu N, Matli MR, Tikishvili E, Welbourn W, Stone S, Shokat KM, and Warren RS.| | UCSF Research Profile
  61. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival.
    Atreya CE, Sangale Z, Xu N, Matli MR, Tikishvili E, Welbourn W, Stone S, Shokat KM, Warren RS| | PubMed
  62. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
    Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS| | PubMed
  63. Personalized Medicine in Oncology
    Atreya CE, Ostrem JM, and Kelley RK.| | UCSF Research Profile
  64. Predictive biomarkers in advance of a companion drug: ahead of their time?
    Kelley RK, Atreya C, Venook AP, Febbo PG| | PubMed
  65. Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.
    Atreya CE, Ducker GS, Feldman ME, Bergsland EK, Warren RS, Shokat KM| | PubMed